A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Phase 3
675
about 6 years
2–11
30 sites in AR, CA, FL +16
What this study is about
This trial is testing whether oral upadacitinib or subcutaneous dupilumab is better at controlling moderate to severe atopic dermatitis in children aged 2 to under 12. Participants will receive either upadacitinib (taken daily) or dupilumab (given every 2 or 4 weeks), and it will last for about 2 years, with regular visits to monitor their condition and check for side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dupilumab
- 2.Take Upadacitinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dupilumab, upadacitinib
oral (Oral Solution)
Primary: Number of Participants with Adverse Events (AEs)
Dermatology